Standout Papers

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Sev... 2020 2026 2022 2024238
  1. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis (2020)
    Emma Guttman‐Yassky, Andrew Blauvelt et al. JAMA Dermatology

Immediate Impact

65 standout
Sub-graph 1 of 21

Citing Papers

Atopic dermatitis
2025 Standout
ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis
2025 Standout
14 intermediate papers

Works of Janice Drew being referenced

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
2020 Standout
Lebrikizumab, a High-Affinity IL-13 Inhibitor, Improves Clinical Manifestations in Moderate-to-Severe Atopic Dermatitis: Primary Results From a Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Phase 2b Study
2019

Author Peers

Author Last Decade Papers Cites
Janice Drew 247 271 391 21 663
Tomoko Maeda‐Chubachi 96 307 319 25 613
Yan HongBo 81 244 456 12 627
Simon Nigen 90 336 437 25 671
Richard Woolf 88 424 296 28 684
Alexandra Gruber‐Wackernagel 93 394 480 29 680
Jamie Weisman 106 216 573 16 685
Anders Johannesson 40 352 333 24 673
Hanne Norsgaard 131 405 379 23 635
R. Marks 87 121 328 32 633
E. Castela 51 421 425 14 822

All Works

Loading papers...

Rankless by CCL
2026